FIGHTING FOR THE
RIGHT TO EQUITABLE ACCESS TO MEDICINE FOR ALL DEVELOPING COUNTRIES
Your donation will help Cheri Nel’s court case against Big Pharma
FIGHTING FOR THE
RIGHT TO EQUITABLE ACCESS TO MEDICINE FOR ALL DEVELOPING COUNTRIES
Your donation will help Cheri Nel’s court case against Big Pharma
CHERI'S STORY
Cheri Nel, a 39-year-old chartered account and corporate investment banker, was diagnosed with cystic fibrosis (CF) – a rare, life-shortening genetic disease – at the age of 6. She’s married to Rob and, together with their three Belgian Malinois, live in the bustling city of Johannesburg, South Africa.
Cheri is eligible for Vertex Pharmaceuticals’ triple therapy, Trikafta. Vertex has registered patents over Trikafta in most countries around the world, including South Africa, but Vertex has not brought this medicine to South Africa. And in countries where it does sell Trikafta, it demands an impossible price – USD 311,000 per year per patient for life.
Cheri’s Story
Cheri Nel, a 39-year-old chartered account and corporate investment banker, was diagnosed with cystic fibrosis (CF) – a rare, life-shortening genetic disease – at the age of 6. She’s married to Rob and, together with their three Belgian Malinois, live in the bustling city of Johannesburg, South Africa.
Cheri is eligible for Vertex Pharmaceuticals’ triple therapy, Trikafta. Vertex has registered patents over Trikafta in most countries around the world, including South Africa, but Vertex has not brought this medicine to South Africa. And in countries where it does sell Trikafta, it demands an impossible price – USD 311,000 per year per patient for life.
162 428
PEOPLE ESTIMATED TO BE LIVING WITH CF GLOBALLY (2022)
412
SOUTH AFRICAN CF PATIENTS ELIGIBLE FOR TRIKAFTA (2021)
523
REGISTERED CF PATIENTS IN SOUTH AFRICA (2021)
17
CF PATIENTS DECEASED IN SOUTH AFRICA (2021)
28.1 YEARS
MEDIAN AGE AT DEATH OF CF PATIENTS IN SOUTH AFRICA (2021)
65+ YEARS
LIFE EXPECTANCY OF CF PATIENTS WHEN USING TRIKAFTA
(2020)
$322,000
PRICE OF TRIKAFTA PER PATIENT PER ANNUM (± R6 MILLION) (2023)
$6,000
ESTIMATED PRODUCTION COST OF TRIKAFTA PER PATIENT PER ANNUM (2023)
$9.7 BILLION
VERTEX’S PROJECTED REVENUE FROM CF PRODUCTS FOR FY23 (2023)
Upholds Human Rights Preserve Justice
CFTR modulators can transform CF from a severe, life-threatening condition into a manageable chronic illness. This court case aims to break the global monopoly of powerful CFTR modulator drugs.
UPHOLD HUMAN RIGHTS
CFTR modulators can transform CF from a severe, life-threatening condition into a manageable chronic illness. This court case aims to break the global monopoly of powerful CFTR modulator drugs.
